A novel immunotherapy for Alzheimer's disease: Antibodies against the β-secretase cleavage site of APP

Current Alzheimer Research

Volumn 4, Issue 4, 2007, Pages 437-445

  Arbel, Michal ^a   Solomon, Beka ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

secretase site; A ; Alzheimer's disease; APP; BACE1; Endocytic pathway; Intracellular A ; Monoclonal antibodies

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BETA SECRETASE INHIBITOR; GAMMA SECRETASE; KMI 429; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BBS1; OM 00 3; OMM 99 2; PROTEINASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIGEN BINDING; AUTOPSY; BRAIN; BRAIN TISSUE; CHO CELL; CONFERENCE PAPER; ENDOSOME; ENZYME ACTIVITY; ENZYME INHIBITION; IMMUNOTHERAPY; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIBODIES; HUMANS; IMMUNOTHERAPY;

EID: 34548681841     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720507781788792     Document Type: Conference Paper

References (74)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741 (2001).
2. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353 (2002).
3. Hardy J and Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12: 383 (1991).
4. Selkoe DJ. Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 271: 18295 (1996).
5. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20: 154 (1997).
6. Busciglio J, Lorenzo A, Yeh J and Yankner BA. Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14: 879 (1995).
7. Gotz J, Probst A, Spillantini MG, Schafer T, Jakes R, Burki K, et al. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. Embo J 14: 1304 (1995).
8. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487 (2001).
9. Hardy J, Duff K, Hardy KG, Perez-Tur J and Hutton M. Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat Neurosci 1: 355 (1998).
10. Sisodia SS and St George-Hyslop PH. gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 3: 281 (2002).
11. Meziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, et al. Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci USA 95: 12683 (1998).
12. Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 77: 1081 (1997).
13. Dewachter I and Van Leuven F. Secretases as targets for the treatment of Alzheimer's disease: the prospects. Lancet Neurol 1: 409 (2002).
14. Haass C and Steiner H. Alzheimer disease gamma-secretase: a complex story of GxGD-type presenilin proteases. Trends Cell Biol 12: 556 (2002).
15. De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 38: 9 (2003).
16. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ and Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 89: 629 (1997).
17. Wong PC, Zheng H, Chen H, Becher MW, Sirinathsinghji DJ, Trumbauer ME, et al. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature 387: 288 (1997).
18. Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405: 689 (2000).
19. Wolfe MS, Xia W, Moore CL, Leatherwood DD, Ostaszewski B, Rahmati T, et al. Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease. Biochemistry 38: 4720 (1999).
20. Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, et al. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry 39: 8698 (2000).
21. Barten DM, Meredith JE, Zaczek R, Houston JG and Albright CF. Gamma-Secretase Inhibitors for Alzheimer's Disease : Balancing Efficacy and Toxicity. Drugs R D 7: 87 (2006).
22. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735 (1999).
23. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402: 537 (1999).
24. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402: 533 (1999).
25. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 14: 419 (1999).
26. Citron M. Beta-secretase as a target for the treatment of Alzheimer's disease. J Neurosci Res 70: 373 (2002).
27. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 4: 233 (2001).
28. Bennett BD, Babu-Khan S, Loeloff R, Louis JC, Curran E, Citron M, et al. Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem 275: 20647 (2000).
29. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4: 231 (2001).
30. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 10: 1317 (2001).
31. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290: 150 (2000).
32. Turner RT, 3rd, Koelsch G, Hong L, Castanheira P, Ermolieff J, Ghosh AK, et al. Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design. Biochemistry 40: 10001 (2001).
33. Hom RK, Fang LY, Mamo S, Tung JS, Guinn AC, Walker DE, et al. Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase. J Med Chem 46: 1799 (2003).
34. Chang WP, Koelsch G, Wong S, Downs D, Da H, Weerasena V, et al. In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J Neurochem 89: 1409 (2004).
35. Kimura T, Shuto D, Kasai S, Liu P, Hidaka K, Hamada T, et al. KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine. Bioorg Med Chem Lett 14: 1527 (2004).
36. Asai M, Hattori C, Iwata N, Saido TC, Sasagawa N, Szabo B, et al. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 96: 533 (2006).
37. Pangalos MN, Jacobsen SJ and Reinhart PH. Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide. Biochem Soc Trans 33: 553 (2005).
38. Lichtenthaler SF, Dominguez DI, Westmeyer GG, Reiss K, Haass C, Saftig P, et al. The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem 278: 48713 (2003).
39. Kitazume S, Tachida Y, Oka R, Kotani N, Ogawa K, Suzuki M, et al. Characterization of alpha 2,6-sialyltransferase cleavage by Alzheimer's beta -secretase (BACE1). J Biol Chem 278: 14865 (2003).
40. Pastorino L, Ikin AF, Lamprianou S, Vacaresse N, Revelli JP, Platt K, et al. BACE (beta-secretase) modulates the processing of APLP2 in vivo. Mol Cell Neurosci 25: 642 (2004).
41. Capell A, Meyn L, Fluhrer R, Teplow DB, Walter J and Haass C. Apical sorting of beta-secretase limits amyloid beta-peptide production. J Biol Chem 277: 5637 (2002).
42. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41: 27 (2004).
43. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25: 11693 (2005).
44. Chyung JH and Selkoe DJ. Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid beta-protein at the cell surface. J Biol Chem 278: 51035 (2003).
45. Koo EH and Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem 269: 17386 (1994).
46. Perez RG, Squazzo SL and Koo EH. Enhanced release of amyloid beta-protein from codon 670/671 "Swedish" mutant beta-amyloid precursor protein occurs in both secretory and endocytic pathways. J Biol Chem 271: 9100 (1996).
47. Soriano S, Chyung AS, Chen X, Stokin GB, Lee VM and Koo EH. Expression of beta-amyloid precursor protein-CD3gamma chimeras to demonstrate the selective generation of amyloid beta(1-40) and amyloid beta(1-42) peptides within secretory and endocytic compartments. J Biol Chem 274: 32295 (1999).
48. Perez RG, Soriano S, Hayes JD, Ostaszewski B, Xia W, Selkoe DJ, et al. Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. J Biol Chem 274: 18851 (1999).
49. Nixon RA, Mathews PM and Cataldo AM. The neuronal endosomal-lysosomal system in Alzheimer's disease. J Alzheimers Dis 3: 97 (2001).
50. Huse JT, Pijak DS, Leslie GJ, Lee VM and Doms RW. Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. J Biol Chem 275: 33729 (2000).
51. Walter J, Fluhrer R, Hartung B, Willem M, Kaether C, Capell A, et al. Phosphorylation regulates intracellular trafficking of beta-secretase. J Biol Chem 276: 14634 (2001).
52. Koo EH, Squazzo SL, Selkoe DJ and Koo CH. Trafficking of cell-surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody. J Cell Sci 109 ( Pt 5): 991 (1996).
53. Kinoshita A, Fukumoto H, Shah T, Whelan CM, Irizarry MC and Hyman BT. Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci 116: 3339 (2003).
54. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240: 622 (1988).
55. Gutman CR, Strittmatter WJ, Weisgraber KH and Matthew WD. Apolipoprotein E binds to and potentiates the biological activity of ciliary neurotrophic factor. J Neurosci 17: 6114 (1997).
56. Laskowitz DT, Horsburgh K and Roses AD. Apolipoprotein E and the CNS response to injury. J Cereb Blood Flow Metab 18: 465 (1998).
57. Permanne B, Perez C, Soto C, Frangione B and Wisniewski T. Detection of apolipoprotein E/dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants. Biochem Biophys Res Commun 240: 715 (1997).
58. Webster S and Rogers J. Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation. J Neurosci Res 46: 58 (1996).
59. Wood SJ, Chan W and Wetzel R. Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry 35: 12623 (1996).
60. Jordan J, Galindo MF, Miller RJ, Reardon CA, Getz GS and LaDu MJ. Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J Neurosci 18: 195 (1998).
61. Miyata M and Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 14: 55 (1996).
62. Cataldo AM, Barnett JL, Pieroni C and Nixon RA. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J Neurosci 17: 6142 (1997).
63. Grbovic OM, Mathews PM, Jiang Y, Schmidt SD, Dinakar R, Summers-Terio NB, et al. Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. J Biol Chem 278: 31261 (2003).
64. Mathews PM, Guerra CB, Jiang Y, Grbovic OM, Kao BH, Schmidt SD, et al. Alzheimer's disease-related overexpression of the cation-dependent mannose 6-phosphate receptor increases Abeta secretion: role for altered lysosomal hydrolase distribution in beta-amyloidogenesis. J Biol Chem 277: 5299 (2002).
65. Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 85: 5409 (1988).
66. Kohler G and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495 (1975).
67. Arbel M, Yacoby I and Solomon B. Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies. Proc Natl Acad Sci USA 102: 7718 (2005).
68. Ehehalt R, Keller P, Haass C, Thiele C and Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160: 113 (2003).
69. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, et al. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 2: 93 (1996).
70. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46: 860 (1999).
71. Billings LM, Oddo S, Green KN, McGaugh JL and LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45: 675 (2005).
72. Paganetti P, Calanca V, Galli C, Stefani M and Molinari M. Betasite specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide. J Cell Biol 168: 863 (2005).
73. Solomon B. Alzheimer's Disease and Immunotherapy. Curr Alzh Res 1: 149 (2004).
74. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156: 15 (2000).